PreprintCase ReportVersion 2Preserved in Portico This version is not peer-reviewed
Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide
Version 1
: Received: 8 July 2020 / Approved: 9 July 2020 / Online: 9 July 2020 (07:54:22 CEST)
Version 2
: Received: 1 August 2020 / Approved: 2 August 2020 / Online: 2 August 2020 (18:16:20 CEST)
How to cite:
Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide. Preprints2020, 2020070178. https://doi.org/10.20944/preprints202007.0178.v2
Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide . Preprints 2020, 2020070178. https://doi.org/10.20944/preprints202007.0178.v2
Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide. Preprints2020, 2020070178. https://doi.org/10.20944/preprints202007.0178.v2
APA Style
Youssef, J.G., Zahiruddin, F., Al-Saadi, M., Yau, S., Goodarzi, A., Huang, H.J., & Javitt, J.C. (2020). Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide<strong> </strong>. Preprints. https://doi.org/10.20944/preprints202007.0178.v2
Chicago/Turabian Style
Youssef, J.G., Howard J. Huang and Jonathan C. Javitt. 2020 "Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide<strong> </strong>" Preprints. https://doi.org/10.20944/preprints202007.0178.v2
Abstract
RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) is shown to block replication of the SARS-CoV-2 virus and has been granted Fast Track Designation by the US FDA for the treatment of Critical COVID-19 with Respiratory Failure. We describe the clinical course of the first patient treated with this investigational medication in an open label manner -- a 54 year old patient suffering antibody-mediated rejection of his double lung transplant who contracted COVID-19 with respiratory failure refractory to all currently available therapies. He received three infusions of RLF-100 under an FDA-approved emergency use IND. Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted. He was discharged from intensive care at that point and scheduled for discharge to home at 1 week on room air. Despite an intervening hospitalization for trauma, he remains alive and free of respiratory failure at 28 days post treatment.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
2 August 2020
Commenter:
Alexander Otth
The commenter has declared there is no conflict of interests.
Comment:
Dear Doctor Javitt
I have been following the Aviptadil story for quite some time now, and your latest update leaves me to believe that we have a real success here. Would you care to comment on this briefly? Will this drug be available soon to cure so many patients suffering from severe lung problems due to Covid 19?
Thank you in advance and all the best to you and your team,
Commenter: Jonathan Javitt
Commenter's Conflict of Interests: Author
Commenter: Alexander Otth
The commenter has declared there is no conflict of interests.
I have been following the Aviptadil story for quite some time now, and your latest update leaves me to believe that we have a real success here. Would you care to comment on this briefly? Will this drug be available soon to cure so many patients suffering from severe lung problems due to Covid 19?
Thank you in advance and all the best to you and your team,
Kind regards from Switzerland,
Alexander Otth